Alpha 2.0
Login Register
» Journals » Blood Cancer J

Blood Cancer Journal

Blood Cancer Journal is a peer-reviewed open-access journal that focuses on all aspects of hematological malignancies. It publishes high-quality research articles, reviews, and case reports, providing a platform for the dissemination of cutting-edge knowledge in the field. With a multidisciplinary approach, the journal aims to advance understanding, diagnosis, and treatment of blood cancers, fostering collaboration among researchers, clinicians, and scientists worldwide.
Details
Abbr. Blood Cancer J
Start 2011
End Continuing
Frequency Irregular
e-ISSN 2044-5385
Country United States
Language English
Metrics
h-index / Ranks: 4647 76
SJR / Ranks: 375 3974
CiteScore / Ranks: 763 13.40
JIF / Ranks: 296 12.8
Recent Articles
21.
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
Xue R, Dai M, Jiang E, Ou X, Huang F, Fan Z, et al.
Blood Cancer J . 2025 Feb; 15(1):21. PMID: 39971949
No abstract available.
22.
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, et al.
Blood Cancer J . 2025 Feb; 15(1):20. PMID: 39966346
Risk stratification models based on cytogenetics and disease burden help identify high-risk patients with newly diagnosed multiple myeloma (NDMM). However, some high-risk patients remain undetected. This study evaluated the prognostic...
23.
Correction: A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
Singh C, Ks L, Jain A, Lad D, Khadwal A, Basher R, et al.
Blood Cancer J . 2025 Feb; 15(1):18. PMID: 39948073
No abstract available.
24.
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block
Ma J, Sun S, Xie Y, Zhou S, Wu M, Zuo X, et al.
Blood Cancer J . 2025 Feb; 15(1):19. PMID: 39948069
No abstract available.
25.
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
Shen J, Shan M, Chu M, Cai Y, Rui J, Chen S, et al.
Blood Cancer J . 2025 Feb; 15(1):17. PMID: 39934109
No abstract available.
26.
Defining 'Intention' in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
Milrod C, Steuer R, Pelcovits A
Blood Cancer J . 2025 Feb; 15(1):16. PMID: 39922824
No abstract available.
27.
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Mukhopadhyay P, Abdullah H, Opalinska J, Paka P, Richards E, Weisel K, et al.
Blood Cancer J . 2025 Feb; 15(1):15. PMID: 39920159
Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti-B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval...
28.
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Costa L, Medvedova E, Dhakal B, Dholaria B, Godby K, Bal S, et al.
Blood Cancer J . 2025 Feb; 15(1):13. PMID: 39910064
No abstract available.
29.
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Chu Y, Zhou B, Gao R, Miao M, Qiu H, Tang X, et al.
Blood Cancer J . 2025 Feb; 15(1):11. PMID: 39910042
No abstract available.
30.
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
Fonseca R, Zhu Y, Bruins L, Ahmann J, de Bonolo Campos C, Braggio E, et al.
Blood Cancer J . 2025 Feb; 15(1):10. PMID: 39910038
Investigating venetoclax (VTX) resistance in multiple myeloma (MM) is crucial for the development of novel therapeutic strategies to tackle resistance. We conducted a multi-omic characterization of established VTX-resistant isogenic human...